Overview

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

Status:
Withdrawn
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a pilot study examining biological endpoints in men with localized prostate cancer who are scheduled to have radical prostatectomies and men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS) following botulinum toxin type A (BoNT-A) injection. Patients will serve as their own controls by receiving BoNT-A injections into the right peripheral and transition zones and sham saline injections into the left peripheral and transition zones.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Treatments:
Botulinum Toxins, Type A
onabotulinumtoxinA